Skip to content

Homoeopathy as an adjuvant for Trigeminal Neuralgia

Management of Trigeminal Neuralgia with Homoeopathic Intervention as an add-on to the Standard treatment ââ?¬â?? A double blind, randomised controlled trial - TN-HOM

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/01/023053
Enrollment
60
Registered
2020-01-30
Start date
Unknown
Completion date
Unknown
Last updated
2026-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: G500- Trigeminal neuralgia

Interventions

Intervention1: Homoeopathy as an adjuvant to Allopathy: Homoeopathy drugs widely used in treating Trigeminal Neurlagia will be used, in addition to allopathic drugs. Dose- As per discretion of the pre

Sponsors

Central Council for Research in Homoeopathy
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients presenting with the following symptoms, according to the International Classification of Headache Society: A. At least three attacks of unilateral facial pain fulfilling criteria B and C B. Occurring in one or more divisions of the trigeminal nerve, with no radiation beyond the trigeminal distribution C. Pain has at least three of the following four characteristics: i. recurring in paroxysmal attacks lasting from a fraction of a second to 2 minutes ii. severe intensity iii. electric shock-like, shooting, stabbing or sharp in quality iv. precipitated by innocuous stimuli to the affected side of the face D. No clinically evident neurological deficit E. Not better accounted for by another ICHD-3 diagnosis 2. Written Informed consent from the patient

Exclusion criteria

Exclusion criteria: 1. Trigeminal Neuralgia due to secondary causes like tumor, multiple sclerosis, dental caries, mandibular osteomyelitis, chronic migraine, post-herpetic neuralgia, temporal arteritis, maxillary sinusitis, etc. [Exclusion by MRI] 2. Severe, advanced cases of systemic diseases like cardiovascular, endocrinal diseases or other disorders.

Design outcomes

Primary

MeasureTime frame
Change in BPI-Facial ScoreTimepoint: BPI-Facial Score in 3 months

Secondary

MeasureTime frame
Change in total and individual domain scores in BPI-FacialTimepoint: 6 months

Countries

India

Contacts

Public ContactProf Dr M M Mehndiratta

Central Council for Research in Homoeopathy

anil23101961@gmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Jun 27, 2026